857 related articles for article (PubMed ID: 10729145)
1. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).
Morello CS; Cranmer LD; Spector DH
J Virol; 2000 Apr; 74(8):3696-708. PubMed ID: 10729145
[TBL] [Abstract][Full Text] [Related]
2. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.
Ye M; Morello CS; Spector DH
J Virol; 2002 Mar; 76(5):2100-12. PubMed ID: 11836387
[TBL] [Abstract][Full Text] [Related]
3. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.
Morello CS; Ye M; Spector DH
J Virol; 2002 May; 76(10):4822-35. PubMed ID: 11967299
[TBL] [Abstract][Full Text] [Related]
4. In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83).
Morello CS; Cranmer LD; Spector DH
J Virol; 1999 Sep; 73(9):7678-93. PubMed ID: 10438858
[TBL] [Abstract][Full Text] [Related]
5. DNA immunization confers protection against murine cytomegalovirus infection.
González Armas JC; Morello CS; Cranmer LD; Spector DH
J Virol; 1996 Nov; 70(11):7921-8. PubMed ID: 8892915
[TBL] [Abstract][Full Text] [Related]
6. Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.
Ye M; Morello CS; Spector DH
J Virol; 2004 Oct; 78(20):11233-45. PubMed ID: 15452242
[TBL] [Abstract][Full Text] [Related]
7. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.
Morello CS; Ye M; Hung S; Kelley LA; Spector DH
J Virol; 2005 Jan; 79(1):159-75. PubMed ID: 15596812
[TBL] [Abstract][Full Text] [Related]
8. Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice.
Huang C; Wang H; Wu S; Chang H; Liu L; Peng B; Fang F; Chen Z
Virol J; 2014 Jun; 11():104. PubMed ID: 24898886
[TBL] [Abstract][Full Text] [Related]
9. Identification, analysis, and evolutionary relationships of the putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 (pp71) and UL83 (pp65) matrix phosphoproteins.
Cranmer LD; Clark CL; Morello CS; Farrell HE; Rawlinson WD; Spector DH
J Virol; 1996 Nov; 70(11):7929-39. PubMed ID: 8892916
[TBL] [Abstract][Full Text] [Related]
10. Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition.
Lyons PA; Allan JE; Carrello C; Shellam GR; Scalzo AA
J Gen Virol; 1996 Oct; 77 ( Pt 10)():2615-23. PubMed ID: 8887498
[TBL] [Abstract][Full Text] [Related]
11. Protective immunization against murine cytomegalovirus infection using adenoviruses and poxviruses expressing hepatitis B virus chimeras.
de Andrade BP; Gazzinelli RT; Del Val M; Bruna-Romero O
Int Microbiol; 2007 Dec; 10(4):261-9. PubMed ID: 18228223
[TBL] [Abstract][Full Text] [Related]
12. High-frequency interferon-gamma-secreting splenocytes specific for murine cytomegalovirus immediate-early-1 (IE-1) peptide 168YPHFMPTNL176 are insufficient to provide complete protection from viral challenge.
Morley PJ; Ertl PF; Sweet C
J Med Virol; 2003 Feb; 69(2):240-50. PubMed ID: 12683414
[TBL] [Abstract][Full Text] [Related]
13. Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV.
Liu G; Zhang F; Wang R; London L; London SD
FASEB J; 2014 Apr; 28(4):1698-710. PubMed ID: 24391133
[TBL] [Abstract][Full Text] [Related]
14. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant.
MacDonald MR; Li XY; Stenberg RM; Campbell AE; Virgin HW
J Virol; 1998 Jan; 72(1):442-51. PubMed ID: 9420244
[TBL] [Abstract][Full Text] [Related]
15. Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).
Holtappels R; Podlech J; Grzimek NK; Thomas D; Pahl-Seibert MF; Reddehase MJ
J Virol; 2001 Jul; 75(14):6584-600. PubMed ID: 11413326
[TBL] [Abstract][Full Text] [Related]
16. Immunisation of Balb/c mice with severely attenuated murine cytomegalovirus mutants induces protective cellular and humoral immunity.
Morley PJ; Ertl P; Sweet C
J Med Virol; 2002 Jun; 67(2):187-99. PubMed ID: 11992579
[TBL] [Abstract][Full Text] [Related]
17. An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV.
Wang H; Yao Y; Huang C; Fu X; Chen Q; Zhang H; Chen J; Fang F; Xie Z; Chen Z
BMC Infect Dis; 2014 Apr; 14():195. PubMed ID: 24720840
[TBL] [Abstract][Full Text] [Related]
18. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.
Endresz V; Kari L; Berencsi K; Kari C; Gyulai Z; Jeney C; Pincus S; Rodeck U; Méric C; Plotkin SA; Gönczöl E
Vaccine; 1999 Jan; 17(1):50-8. PubMed ID: 10078607
[TBL] [Abstract][Full Text] [Related]
19. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.
Pahl-Seibert MF; Juelch M; Podlech J; Thomas D; Deegen P; Reddehase MJ; Holtappels R
J Virol; 2005 May; 79(9):5400-13. PubMed ID: 15827154
[TBL] [Abstract][Full Text] [Related]
20. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
